A newly identified protein interaction that affects cell cycle regulation may be an attractive target for cancer therapy.
Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular “inboxes” that are targeted by up to half of all pharmaceuticals.
Understanding how the main receptor for light interacts with other signaling molecules may inform new pharmaceutical development.
Several Vanderbilt researchers have collaborated with this year’s Nobel Chemistry winners.
A reversible chemical modification of rhodopsin, a receptor for light, plays a role in the degeneration of retinal cells.
Accessibility Tools